Wednesday, February 10, 2010, 12:23am EST - Canadian Markets open in 9 hours and 7 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

GenVec Inc. (GNVC)

 On Feb 9: 1.72 USD  Up 0.04 (2.38%)  
MORE ON GNVC
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
GenVec, Inc. (NGM:GNVC) Delayed quote dataEdit
After Hours: 1.71 Down 0.01 (0.58%) as of 7:24pm EST on 02/09/10
Last Trade: 1.72 USD
Trade Time: Feb 9
Change: Up 0.04 (2.38%)
Prev Close: 1.68
Open: 1.70
Bid: 1.47 x 4500
Ask: 1.88 x 1200
1y Target Est: 4.00
Day's Range: 1.68 - 1.74
52wk Range: 0.33 - 3.34
Volume: 1,641,271
Avg Vol (3m): 3,662,130
Market Cap: 182.90M
P/E (ttm): N/A
EPS (ttm): -0.22
Div & Yield: N/A (N/A%)
GenVec Inc. (GNVC)
1d  5d  3m  6m  1y  2y  5y  max 
 Add GNVC to Portfolio   Download Data

HEADLINES
• 3 Stocks in a Tailspin
at Motley Fool (Thu, Feb 4)
• 10 Biotech Stocks on Clinical Trials Watch
at TheStreet.com (Thu, Feb 4)
• Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering
PRNewswire (Mon, Feb 1)
• GenVec to Present at the 12th Annual BIO CEO & Investor Conference
PRNewswire (Mon, Feb 1)
• Biotech Stock Mailbag: Keryx Biopharmaceuticals
at TheStreet.com (Fri, Jan 29)
• Wednesday's Biggest Stock Stars
at Motley Fool (Thu, Jan 28)
• More Biotech Volatility: Celsius Holdings, Genvec
at Seeking Alpha (Thu, Jan 28)
• GENVEC INC Files SEC form 8-K, Financial Statements and Exhibits
EDGAR Online (Wed, Jan 27)
• Jackson Hewitt Tax Service, GenVec: Biggest Price Decliners (JTX, GNVC)
at The Wall Street Journal Online (Wed, Jan 27)
• Conolog, Jackson Hewitt: Late Day Volume Plays
at TheStreet.com (Wed, Jan 27)
• Jackson Hewitt Tax Service, GenVec: Biggest Price Decliners (MLP, GNVC)
at The Wall Street Journal Online (Wed, Jan 27)
More Headlines for GNVC...
ANALYST
EPS Est (next year) (Dec-09) : -0.17
EPS Est (in 2 years) (Dec-10) : -0.18
Avg Rec (current)*: 2.0
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
GenVec, Inc., a clinical stage biopharmaceutical company, develops gene-based therapeutic drugs and vaccines in the United States. Its lead therapeutic product candidate, TNFerade biologic, is under Phase III trial for first-line treatment of inop...

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices